Page 47 - Read Online

Page 302 Cancer Drug Resist 2018;1:266-302 I http://dx.doi.org/10.20517/cdr.2018.18
3 Institute of Medical Virology, Clinics of the Goethe-University, Frankfurt am Main, Germany

Drug resistance is the most common cause of failure of anti-cancer drug therapies. Nanoparticles have
been introduced as drug carrier systems for the targeting of tumours and overcoming drug resistance.
Here, we investigate the sensitivity of cancer cells to doxorubin-loaded nanoparticles made from different
materials, using a panel of neuroblastoma cell lines and their doxorubicin and vincristine sub-lines.

66. Characterisation of triple negative breast cancer cell lines adapted to paclitaxel

2
1
1
1
Eithaar M. Al-Barwani , Jindrich Cinatl Jr , Mark N. Wass , Martin Michaelis
1 School of Biosciences, University of Kent, Canterbury, UK
2 Institute of Medical Virology, Clinics of the Goethe-University, Frankfurt am Main, Germany
Triple negative breast cancer (TNBC) is a specific subtype of breast cancer that is negative for the protein
expression of the oestrogen receptor, progesterone receptor and Human epidermal growth factor receptor
2. TNBC constitutes 15%-25% of all breast cancers and has been established as being a very aggressive sub-
type, despite patients having good initial responses to chemotherapy. One of the chemotherapeutic agents
most commonly used as a first line of treatment in TNBC is the microtubule-binding agent paclitaxel.
Here we introduce a novel panel of TNBC cell lines adapted to paclitaxel including drug sensitivity profiles
against a range of cancer agents.

67. Characterisation of non-small cell lung cancer with epidermal growth factor receptor
mutation

Tharsagini Nanthaprakash , Jindrich Cinatl Jr , Mark N. Wass , Martin Michaelis 1
1
2
1
1 School, of Biosciences, University of Kent, Canterbury, UK
2 Institute of Medical Virology, Clinics of the Goethe-University, Frankfurt am Main, Germany

Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer-related deaths and is the most
common type of lung cancer (87%) in the UK. Approximately 70% of the patients present with locally
advanced or metastatic disease at the time of the diagnosis left with chemotherapy as the most beneficial
option. NSCLCs harbouring tumour cells characterised by activating epidermal growth factor receptor
(EGFR) mutations are typically treated using EGFR tyrosine kinase inhibitors (TKIs). However, resistance
formation is inevitable and multiple mechanisms of TKIs resistance have been reported in EGFR-mutant
NSCLC. Here, we introduce a novel panel of models of acquired EGFR-TKI resistance in NSCLC based on
the EGFR-mutant NSCLC cell lines HCC4006 and HCC827 and their sub-lines adapted to the first genera-
tion EGFR-TKIs Erlotinib and Gefitinib and the second generation EGFR-TKI Afatinib.